Abstract

The chemotherapeutic use of cisplatin is limited by its severe side effects. In this study, by conducting different omics data analyses, we demonstrated that cisplatin induces cell death in a proximal tubular cell line by suppressing glycolysis- and tricarboxylic acid (TCA)/mitochondria-related genes. Furthermore, analysis of the urine from cisplatin-treated rats revealed the lower expression levels of enzymes involved in glycolysis, TCA cycle, and genes related to mitochondrial stability and confirmed the cisplatin-related metabolic abnormalities. Additionally, an increase in the level of p53, which directly inhibits glycolysis, has been observed. Inhibition of p53 restored glycolysis and significantly reduced the rate of cell death at 24 h and 48 h due to p53 inhibition. The foremost reason of cisplatin-related cytotoxicity has been correlated to the generation of mitochondrial reactive oxygen species (ROS) that influence multiple pathways. Abnormalities in these pathways resulted in the collapse of mitochondrial energy production, which in turn sensitized the cells to death. The quenching of ROS led to the amelioration of the affected pathways. Considering these observations, it can be concluded that there is a significant correlation between cisplatin and metabolic dysfunctions involving mROS as the major player.

Highlights

  • Platinum-derived chemotherapeutic agents, including the parent compound cis-diamminedichloroplatinum (II), are the principal therapeutic agents to treat various cancers, including ovarian, testicular, and bladder cancer [1,2]

  • We found that cell proliferation was decreased in a dose- and time-dependent manner

  • Cell damage was quantified in cells treated with cisplatin for 24 h using the lactate dehydrogenase (LDH) assay (Fig 1B)

Read more

Summary

Introduction

Platinum-derived chemotherapeutic agents, including the parent compound cis-diamminedichloroplatinum (II) (cisplatin), are the principal therapeutic agents to treat various cancers, including ovarian, testicular, and bladder cancer [1,2]. The therapeutic use of cisplatin is limited by its irreversible side effects, including transcription inhibition, cell cycle arrest, generation of reactive oxygen species (ROS), and apoptosis [3]. Centers Program (NRF 2012-0006687) and the Ajou university research fund. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.